Payment overview · 2025
General Payments
$603.74
31 reported records · 15 companies
Healthcare provider profile · identity verified
Julia Ann Gilbert, CNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · PORTSMOUTH, OH · NPI 1306171624
Verified facts
What the public records show
CMS Open Payments records show Julia Ann Gilbert, CNP received $603.74 in general payments during 2025 across 31 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $137.46 | 22.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $56.32 | 9.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.18 | 8.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.76 | 8.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $43.87 | 7.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.43 | 7.0% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.43 | 6.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.95 | 5.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.31 | 5.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.09 | 5.0% | 2 | 2025 |
| SPR Therapeutics, Inc | Unresolved — no canonical attribution shown | $18.85 | 3.1% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.44 | 3.0% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $17.59 | 2.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.06 | 2.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.00 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $603.74 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $122.33 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $120.82 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $105.69 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $56.32 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $56.32 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $43.87 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.43 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.43 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $39.43 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.58 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $30.31 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.09 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| SPRINT PNS System Normalized: sprint pns system |
Device | SPR Therapeutics, Inc | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 76 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
76 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 505 | 63 |
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 108 |
| Gabapentin | Gabapentin | 420 | 59 |
| Lisinopril | Lisinopril | 343 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 334 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 324 | 92 |
| Omeprazole | Omeprazole | 312 | 58 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 306 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 67 |
| Furosemide | Furosemide | 239 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 239 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 232 | 44 |
| Metformin Hcl | Metformin Hcl | 199 | 48 |
| Ibuprofen | Ibuprofen | 195 | 45 |
| Alprazolam | Alprazolam | 193 | 26 |
| Buspirone Hcl | Buspirone Hcl | 193 | 48 |
| Potassium Chloride | Potassium Chloride | 189 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 42 |
| Montelukast Sodium | Montelukast Sodium | 158 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 158 | 31 |
| Trazodone Hcl | Trazodone Hcl | 155 | 35 |
| Simvastatin | Simvastatin | 137 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 125 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 123 | 22 |
| Celecoxib | Celecoxib | 121 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 119 | 36 |
| Carvedilol | Carvedilol | 116 | 25 |
| Prednisone | Prednisone | 114 | 64 |
| Losartan Potassium | Losartan Potassium | 113 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 26 |
| Januvia | Sitagliptin Phosphate | 92 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 35 |
| Sertraline Hcl | Sertraline Hcl | 90 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 89 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 16 |
| Xarelto | Rivaroxaban | 88 | 12 |
| Lorazepam | Lorazepam | 87 | 13 |
| Famotidine | Famotidine | 85 | 25 |
| Ozempic | Semaglutide | 83 | 18 |
| Clonazepam | Clonazepam | 81 | 18 |
| Eliquis | Apixaban | 81 | 16 |
| Farxiga | Dapagliflozin Propanediol | 76 | 15 |
| Atenolol | Atenolol | 75 | 14 |
| Sucralfate | Sucralfate | 73 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 18 |
| Allopurinol | Allopurinol | 71 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 70 | 17 |
| Promethazine Hcl | Promethazine Hcl | 70 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 18 |
| Meloxicam | Meloxicam | 69 | 16 |
| Methocarbamol | Methocarbamol | 68 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 13 |
| Pregabalin | Pregabalin | 65 | 14 |
| Spironolactone | Spironolactone | 61 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 59 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 16 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 15 |
| Clonidine Hcl | Clonidine Hcl | 49 | 14 |
| Diazepam | Diazepam | 49 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 13 |
| Trulicity | Dulaglutide | 47 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 29 |
| Jardiance | Empagliflozin | 43 | suppressed |
| Nystatin | Nystatin | 43 | 15 |
| Alendronate Sodium | Alendronate Sodium | 41 | 11 |
| Linzess | Linaclotide | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 32 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | suppressed |
| Fluconazole | Fluconazole | 38 | 22 |
| Spiriva Respimat | Tiotropium Bromide | 37 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 36 | 12 |
| Klor-Con M20 | Potassium Chloride | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 36 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | 19 |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 15 |
| Rizatriptan | Rizatriptan Benzoate | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | 11 |
| Estradiol | Estradiol | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | 11 |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 28 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 11 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 19 |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 20 |
| Rybelsus | Semaglutide | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 18 |
| Anastrozole | Anastrozole | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Trueplus Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $603.74 · 31 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CRYSVITA, Cologuard Collection Kit, FARXIGA, JARDIANCE, Jornay PM, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, SPRINT PNS System, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error